NasdaqGM:PSNLLife Sciences
Personalis (PSNL): Revenue Forecast to Grow 30% Annually, But Losses Continue to Mount
Personalis (PSNL) remains unprofitable, with losses mounting at a pace of 13.5% per year over the last five years. Despite the ongoing red ink, the company is expected to grow revenue at a rapid 30.32% annually, easily outpacing the broader US market's growth rate of 10.5% per year. Investors are closely watching whether this strong top-line forecast can eventually reverse persistent losses, especially as shares trade at an 8.5x Price-to-Sales Ratio, which is far above both peer and industry...